Aurora kinase A

Aurora kinase A

An Aurora kinase encoded by AURKA on chromosome 20q13, which is involved in regulating many mitotic events such as entry into mitosis. Aurora A levels rise during the G2 phase and peak early in mitosis. It regulates centrosome maturation by moderating the recruitment of proteins, such as TPX-2, Ajuba, Bora and Lats, which are essential for accumulating microtubule spindle components (e.g.,gamma-tubulin). Aurora A is associated with separation of centrosomes, phosphorylating the kinesin motor protein, Eg5; it also regulates the microtubule network that forms mitotic spindles by regulating the EXTAH multiprotein complex.
References in periodicals archive ?
AurKa Pharma was established as part of the TVM Life Science Ventures VII fund, to develop an Aurora kinase A inhibitor called AK-01, an oncology compound that was originally discovered through a Lilly research and development program.
Eli Lilly and Company announced an agreement to acquire AurKa Pharma, a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly.
AurKa Pharma is a company established by investment advisory and fund managers group TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly.
It is known that Aurora kinase A and JAK2 pathway activation contributes to GVHD.
Aurora kinase A and JAK2 also significantly reduced GVHD in mice and allowed for the development of anti-cancer immune cells.
Betts et al., "Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining T reg and antitumor CTL function," Science Translational Medicine, 2017; 9 (372): eaai8269 DOI: 10.1126/scitranslmed.aai8269
Li, "Expre ssion of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis," Diagnostic Pathology, vol.
Caldas, "Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer," British Journal of Cancer, vol.
The researchers hypothesized that cotreatment with drugs that target both Aurora kinase A and JAK2 could prevent GVHD better than either drug alone.
Full browser ?